Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
CATHY WOOD ARK GARBAGE ARK Funds Heading for 90% STOCK CRASH! - 22nd Jan 22
Gold Is the Belle of the Ball. Will Its Dance Turn Bearish? - 22nd Jan 22
Best Neighborhoods to Buy Real Estate in San Diego - 22nd Jan 22
Stock Market January PANIC AI Tech Stocks Buying Opp - Trend Forecast 2022 - 21st Jan 21
How to Get Rich in the MetaVerse - 20th Jan 21
Should you Buy Payment Disruptor Stocks in 2022? - 20th Jan 21
2022 the Year of Smart devices, Electric Vehicles, and AI Startups - 20th Jan 21
Oil Markets More Animated by Geopolitics, Supply, and Demand - 20th Jan 21
WARNING - AI STOCK MARKET CRASH / BEAR SWITCH TRIGGERED! - 19th Jan 22
Fake It Till You Make It: Will Silver’s Motto Work on Gold? - 19th Jan 22
Crude Oil Smashing Stocks - 19th Jan 22
US Stagflation: The Global Risk of 2022 - 19th Jan 22
Stock Market Trend Forecast Early 2022 - Tech Growth Value Stocks Rotation - 18th Jan 22
Stock Market Sentiment Speaks: Are We Setting Up For A 'Mini-Crash'? - 18th Jan 22
Mobile Sports Betting is on a rise: Here’s why - 18th Jan 22
Exponential AI Stocks Mega-trend - 17th Jan 22
THE NEXT BITCOIN - 17th Jan 22
Gold Price Predictions for 2022 - 17th Jan 22
How Do Debt Relief Services Work To Reduce The Amount You Owe? - 17th Jan 22
RIVIAN IPO Illustrates We are in the Mother of all Stock Market Bubbles - 16th Jan 22
All Market Eyes on Copper - 16th Jan 22
The US Dollar Had a Slip-Up, but Gold Turned a Blind Eye to It - 16th Jan 22
A Stock Market Top for the Ages - 16th Jan 22
FREETRADE - Stock Investing Platform, the Good, Bad and Ugly Review, Free Shares, Cancelled Orders - 15th Jan 22
WD 14tb My Book External Drive Unboxing, Testing and Benchmark Performance Amazon Buy Review - 15th Jan 22
Toyland Ferris Wheel Birthday Fun at Gulliver's Rother Valley UK Theme Park 2022 - 15th Jan 22
What You Should Know About a TailoredPay High Risk Merchant Account - 15th Jan 22
Best Metaverse Tech Stocks Investing for 2022 and Beyond - 14th Jan 22
Gold Price Lagging Inflation - 14th Jan 22
Get Your Startup Idea Up And Running With These 7 Tips - 14th Jan 22
What Happens When Your Flight Gets Cancelled in the UK? - 14th Jan 22
How to Profit from 2022’s Biggest Trend Reversal - 11th Jan 22
Stock Market Sentiment Speaks: Are We Ready To Drop To 4400SPX? - 11th Jan 22
What's the Role of an Affiliate Marketer? - 11th Jan 22
Essential Things To Know Before You Set Up A Limited Liability Company - 11th Jan 22
NVIDIA THE KING OF THE METAVERSE! - 10th Jan 22
Fiscal and Monetary Cliffs Have Arrived - 10th Jan 22
The Meteoric Rise of Investing in Trading Cards - 10th Jan 22
IBM The REAL Quantum Metaverse STOCK! - 9th Jan 22
WARNING Failing NVME2 M2 SSD Drives Can Prevent Systems From Booting - Corsair MP600 - 9th Jan 22
The Fed’s inflated cake and a ‘quant’ of history - 9th Jan 22
NVME M2 SSD FAILURE WARNING Signs - Corsair MP600 1tb Drive - 9th Jan 22
Meadowhall Sheffield Christmas Lights 2021 Shopping - Before the Switch on - 9th Jan 22
How Does Insurance Work In Europe? Find Out Here - 9th Jan 22
MATTERPORT (MTTR) - DIGITIZING THE REAL WORLD - METAVERSE INVESTING 2022 - 7th Jan 22
Effect of Deflation On The Gold Price - 7th Jan 22
Stock Market 2022 Requires Different Strategies For Traders/Investors - 7th Jan 22
Old Man Winter Will Stimulate Natural Gas and Heating Oil Demand - 7th Jan 22
Is The Lazy Stock Market Bull Strategy Worth Considering? - 7th Jan 22
METAVERSE - NEW LIFE FOR SONY AGEING GAMING GIANT? - 6th Jan 2022
What Elliott Waves Show for Asia Pacific Stock and Financial Markets 2022 - 6th Jan 2022
Why You Should Register Your Company - 6th Jan 2022
4 Ways to Invest in Silver for 2022 - 6th Jan 2022
UNITY (U) - Metaverse Stock Analysis Investing for 2022 and Beyond - 5th Jan 2022
Stock Market Staving Off Risk-Off - 5th Jan 2022
Gold and Silver Still Hungover After New Year’s Eve - 5th Jan 2022
S&P 500 In an Uncharted Territory, But Is Sky the Limit? - 5th Jan 2022

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Regenerative Medicine’s Fountain of Youth

Companies / BioTech Jan 24, 2016 - 04:04 AM GMT

By: Richard_Mills

Companies

Aubrey de Grey a biomedical gerontologist, predicted that the first person to live to a thousand has already been born. According to de Grey the key may lie in the field of regenerative medicine.

The Webster dictionary defines biological regeneration as “the restoration or the growth by an organism of organ or tissue, that have been lost, removed or injured.”

Dr. William Haseltine CEO of Human Genome Sciences, believes thatregenerative medicine is about assisting the body to heal itself. Dr. Haseltine coined the term "regenerative medicine," to describe the expected medical revolution that, in his view, could lead to human immortality.


Stanford Universities Dr. Helen Blau wrote that the goal of regenerative

medicine is to restore form and function to damaged tissues.

I think we can decide for ourselves that regenerative medicine means replacing, engineering or regenerating human cells, tissues or organs with the goal being to re-establish normality for conditions that currently are beyond repair.

“Cell therapy uses living cells as treatments. Its potential to cure or transform serious medical conditions lies in the nature of cells and their ability to interact with the body at levels of complexity many orders of magnitude greater than conventional drugs. Regenerative medicine is focused on the regeneration of tissues and organs using all the different therapeutic platform technologies available: small molecule drugs, biologics, medical devices and cells. Stem cell technologies, cell therapy and regenerative medicine are closely entwined and will ultimately transform the practice of medicine from today’s model of continual interventions to single

treatment cures.” Following Through: Realizing the Promise of Stem Cells, KPMG

Stem cells

Stem cells are the foundation for every organ and tissue in your body.

Stem cell research is paving, or leading the way for the hugely transformative and disruptive potential of regenerative medicine.

There are many different types of stem cells that come from different places in the body or are formed at different times in our lives.

All stem cells can self-renew – clone themselves - and differentiate, meaning they can develop into more specialized cells.

Embryonic stem cells

Embryonic stem cells are obtained from the inner cell mass of the blastocyst, a mainly hollow ball of cells that, in humans, forms three to five days after an egg cell is fertilized by a sperm. Embryonic stem cells are pluripotent, meaning they can give rise to every cell type in the fully formed body, but not the placenta and umbilical cord.

Tissue-specific stem cells

Tissue-specific stem cells (also referred to as somatic or adult stem cells) are more specialized than embryonic stem cells. Typically, these stem cells can generate different cell types for the specific tissue or organ in which they live.

Induced pluripotent stem cells

Induced pluripotent stem (iPS) cells are cells that have been engineered in the lab by converting tissue-specific (somatic/adult) cells, such as skin cells, into cells that behave like embryonic stem cells.

Treatments include both in vivo and in vitro procedures:

  • In vivo - studies and trials performed inside the living body in order to stimulate previously irreparable organs to heal themselves
  • In vito - treatments are applied to the body through implantation of a therapy studied inside the laboratory

Sernova Corp TSX.V – SVA

For the past 25 years, scientific laboratories around the world, with specialty trained experts in cell technologies, were learning the processes for how the body turns starting generalized stem cells into the mature functional cells.

Recent scientific advances have turned these scientists towards developing therapeutic cells to treat diseases such as Diabetes and Hemophilia. If successful these technologies have the ability to treat millions of patients unlike the currently available donor cells. 

The ultimate goal of regenerative medicine for technologies that produce proteins or hormones as therapeutics, is to develop an unlimited supply of safe and efficacious therapeutic stem cells placed, in a simple procedure, within the body in a cell friendly and retrievable medical device, while being protected from immune system attack.

When the time came, Sernova Corp was determined to be in the forefront of such technologies with strong proof of concept on their therapeutic device with donor therapeutic cells within. 

Knowing the importance of these developments, back in 2009, Sernova began working on, and patented, a proprietary, scalable, implantable medical device, their Cell Pouch™ that creates a natural environment for the survival and function of therapeutic cells.

The following examples are two diseases that regenerative medicine for technologies that produce proteins or hormones as therapeutics has the potential to cure and what the current state of treatment looks like.

Haemophilia

Hemophilia A - Occurs in about 1 in 5,000 births. Currently, the number of people with hemophilia in the United States is estimated to be about 20,000, an estimated 400,000 people worldwide are living with hemophilia and only 25% receive adequate treatment.

Hemophilia is passed from parents to children. According to the U.S. Centers for Disease Control and Prevention, hemophilia occurs in approximately one in 5,000 live births. Even though this is an inherited disease, approximately one-third of the cases occur due to spontaneous gene mutation.

Hemophilia is a rare bleeding disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marrow, to help the blood clot.

There are several types of hemophilia, such as, hemophilia A, hemophilia B (commonly known as Christmas disease) and hemophilia C. Hemophilia A is the most common type of the disorder and is caused due to insufficient clotting factor VIII. Hemophilia A is four times more common than hemophilia B (US$2 billion market), and more than half of the patients with hemophilia A have a severe form of hemophilia.

Hemophilia A patients receive prophy-laxis factor replacement therapy. Prophylactic therapy (prevention therapy) involves three infusions of Factor VIII each week at the hospital at a cost of about $260,000 each year.

The broader hemophilia A&B market is US$10 billion and is expected to grow to US$13 billion by 2020.

The European Commission’s Horizon 2020 program has just awarded a $5.6M Euro ($8.5M CAD) grant to the HemAcure consortium. The consortium consists of Sernova Corp and five European academic and private partners to advance development of a GMP clinical grade Factor VIII releasing therapeutic cell product in combination with Sernova’s Cell Pouch(TM) for the treatment of severe hemophilia A.

The product being developed by the HemAcure consortium is expected to be highly disruptive to the current standard of care treatments for hemophilia A.

The reviewof the HemAcure grant proposal stated the following:

“Participation of the third country partner (Sernova Corp) is essential for carrying out the (program). This is justified by the fact that the partner in question is the one who possesses the technology that will be the basis of the whole proposal, and which will perform all the in vivo studies. Sernova uses a scalable, contract manufactured, proprietary patented worldwide implantable medical device (Cell Pouch) transplanted with therapeutic cells. (It) has been in development for more than six years and has shown success in multiple small and large animal preclinical models and is now in a clinical trial for another therapeutic indication. This Cell Pouch device is the only such device that when implanted under the skin is proven to become incorporated with blood vessel enriched tissue-forming chambers for the placement of therapeutic cells. This implies that the Canadian partner (Sernova) is an essential partner for the success of this project.”

About HemAcure

HemAcure is the name of the consortium developing a product for hemophilia A. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 667421. The consortium members include the University Hospital Wurzburg (Coordinating Institute), Integrierte Management Systeme IMS e.K., Universita del Piemonte Orientale “Amedeo Avogadro,” Loughborough University, GABO:mi Gesellschaft für Ablauforganisation: milliarium mbH & Co. and Sernova Corp. The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy within Sernova’s prevascularized Cell Pouch to treat this bleeding disorder that should ultimately lead to improved quality of life of the patients.

Diabetes

The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes is on pace to grow to over $114 billion by 2018.

The top 10 companies producing diabetes medications raked in about $62 billion in global sales in 2014, up 5.1% from the previous year.

“Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.”Analyzing the Global Diabetes Market, researchandmarkets.com

From a recently published paper ‘Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device’ comes the following…

"The emerging field of cellular transplantation involving human-derived engineered stem cells is providing potential therapeutic treatment options to benefit far more patients than donor cells can provide, especially for diseases, such as type 1 diabetes. The future of these therapies, aside from manufacturing aspects to improve safety, depends on a suitable environment for the cells and cellular engraftment.

The current study demonstrates that the CP (Cell Pouch) placed in the subcutaneous space provides a suitable environment for therapeutic islets as effective as the renal subcapsular transplantation, at least in the murine model. Furthermore, in subsequent assessment, it has been shown that the CP scaled for human use can provide glucose control in large animal transplantation models of diabetes (Sernova unpubl. results).

Thus, the CP system placed subcutaneously also meets the requirements for scalable human islet transplantation. Further studies, which include evaluation in the clinic are now required to demonstrate that the CP can indeed serve as a potential alternative to clinical intraportal islet transplantation, and provide a vehicle for future placement of alternate cellular therapies in replacement and regenerative medicine. Indeed, the data presented herein in addition to Sernova's large animal data (unpublished) formed the experimental basis of a first-in-human trial using identical CP technology currently underway in patients at the University of Alberta."

Results from the afore mentioned first-in-human trial using SVA’s Cell Pouch(TM) were impressive…

“Encouraging early results up to 30 days post-islet transplant were presented at the International Pancreas and Islet Transplantation Congress in September, 2013. These results showed after implantation under the skin, the Cell Pouch is safe and biocompatible. Following islet transplantation, the islets living within a natural tissue matrix were supported with a rich supply of blood vessels, similar to the pancreas. Of further importance, the islets were shown to make insulin, somatostatin and glucagon – key hormones in the control of blood sugar levels. The study was conducted with Dr. James Shapiro as principal investigator at the University of Alberta Health Sciences Centre in Edmonton, Alberta.”

Let’s visit SVA’s website from where we get the following…

“In July, 2014 Sernova entered into an agreement with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies. developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes.

A product development program has been designed to advance the technologies from preclinical proof-of-concept studies through to human testing on an expedited basis.

Sernova believes the proprietary product – insulin producing stem cells, protected locally from immune system attack and placed within Sernova’s prevascularized Cell Pouch(TM) – has the potential to provide a significant break-through in the quality of treatment for the tens of millions of people suffering from insulin-dependent diabetes, following successful preclinical and clinical testing. Such individuals could essentially be liberated from their current onerous regime of daily blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life while also reducing short term and longer term health care costs.”

Conclusion

Harnessing the power of stem cells to repair or replace cells, tissues or organs that are damaged by trauma or disease means we are entering an era where treatments for some of the world's most devastating diseases are developed.

Many companies have stem cells, most even have the ability to manufacture them for various indications. In your author’s opinion, only Sernova Corp TSX.V - TSX has a proven safe and biocompatible therapeutic device to host these cells within the human body.

The transformational potential of stem cells, placed within Sernova’s prevascularized Cell Pouch(TM), to cure diabetes and hemophilia could:

  • Treat diseases in a much better way than traditional drugs/treatments
  • Significantly improve the quality of patient’s lives
  • Offer a faster, more complete recovery with significantly fewer side effects or risk of complications
  • Reduce the cost of healthcare
  • Prevent premature mortality
  • Bring significant indirect economic benefits not only to patients but society as a whole

Lab manufactured therapeutic stem cells hosted in the human body, in SVA’s prevascularized Cell Pouch(TM), monitoring, regulating, manufacturing and secreting the necessary hormones, factors and proteins to control diabetes and hemophilia is a milestone accomplishment.

So does Sernova have Ponce De Leon’s fabled Fountain of Youth? No of course not, but it would be hard to argue against my position that Sernova Corp., and the regenerative medicine sector as a whole, has taken a huge step along that road if upcoming human trials are successful.

It is an exciting time for regenerative medicine, the health care sector, patients, and yes investors, with many disruptive innovations on the near horizon.

Sernova Corp TSX.V - SXA is on my radar screen. Is it on yours?

If not, maybe it should be.

By Richard (Rick) Mills

www.aheadoftheherd.com

rick@aheadoftheherd.com

If you're interested in learning more about the junior resource and bio-med sectors please come and visit us at www.aheadoftheherd.com
Site membership is free. No credit card or personal information is asked for.

Richard is host of Aheadoftheherd.com and invests in the junior resource sector.
His articles have been published on over 400 websites, including: Wall Street Journal, Market Oracle, USAToday, National Post, Stockhouse, Lewrockwell, Pinnacledigest, Uranium Miner, Beforeitsnews, SeekingAlpha, MontrealGazette, Casey Research, 24hgold, Vancouver Sun, CBSnews, SilverBearCafe, Infomine, Huffington Post, Mineweb, 321Gold, Kitco, Gold-Eagle, The Gold/Energy Reports, Calgary Herald, Resource Investor, Mining.com, Forbes, FNArena, Uraniumseek, Financial Sense, Goldseek, Dallasnews, Vantagewire, Resourceclips and the Association of Mining Analysts.

Copyright © 2016 Richard (Rick) Mills - All Rights Reserved

Legal Notice / Disclaimer: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Richard Mills has based this document on information obtained from sources he believes to be reliable but which has not been independently verified; Richard Mills makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Richard Mills only and are subject to change without notice. Richard Mills assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, I, Richard Mills, assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.

Richard (Rick) Mills Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in